Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
$10.72
+1.1%
$9.22
$2.31
$13.70
$37.25M-0.6358,386 shs23,114 shs
Imunon, Inc. stock logo
IMNN
Imunon
$8.50
+2.5%
$15.34
$5.55
$47.40
$11.78M1.93424,492 shs106,176 shs
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
$1.42
-6.6%
$1.36
$0.85
$2.09
$39.98M0.4953,208 shs38,919 shs
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
$0.65
+0.2%
$0.72
$0.62
$1.70
$33.60M-0.15346,611 shs663,503 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
+1.13%-7.82%+43.32%+31.53%+122.13%
Imunon, Inc. stock logo
IMNN
Imunon
+2.53%+21.43%-29.17%-32.31%-58.02%
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
-6.58%-0.70%+8.40%+10.94%-33.64%
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
+0.18%-6.70%-6.20%-13.36%-31.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Imunon, Inc. stock logo
IMNN
Imunon
2.4583 of 5 stars
3.45.00.00.01.60.00.6
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
1.4989 of 5 stars
3.05.00.00.00.60.00.0
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
3.2315 of 5 stars
3.54.00.00.02.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
0.00
N/AN/AN/A
Imunon, Inc. stock logo
IMNN
Imunon
2.75
Moderate Buy$232.502,635.29% Upside
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
2.00
Hold$3.17123.00% Upside
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
3.00
Buy$4.00515.38% Upside

Current Analyst Ratings Breakdown

Latest IMNN, COEP, XLO, and LVTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Imunon, Inc. stock logo
IMNN
Imunon
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/19/2025
Imunon, Inc. stock logo
IMNN
Imunon
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
5/15/2025
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
5/13/2025
Imunon, Inc. stock logo
IMNN
Imunon
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$435.00 ➝ $255.00
5/7/2025
Imunon, Inc. stock logo
IMNN
Imunon
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$435.00 ➝ $435.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
$62.87K599.14N/AN/A$1.61 per share6.66
Imunon, Inc. stock logo
IMNN
Imunon
N/AN/AN/AN/A$4.39 per shareN/A
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
$11.98M3.12N/AN/A$1.06 per share1.34
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
$6.34M5.31N/AN/A$0.40 per share1.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
-$10.88M-$5.80N/AN/AN/A-282.39%-127.23%N/A
Imunon, Inc. stock logo
IMNN
Imunon
-$18.62M-$20.39N/AN/AN/AN/A-427.98%-175.03%8/5/2025 (Estimated)
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
-$25.11M-$1.04N/AN/AN/AN/A-86.38%-34.12%8/19/2025 (Estimated)
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
-$58.24M-$0.84N/AN/AN/A-585.54%-262.69%-64.01%8/14/2025 (Estimated)

Latest IMNN, COEP, XLO, and LVTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2025Q2 2025
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
-$0.28N/AN/AN/AN/AN/A
8/14/2025Q2 2025
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
-$0.10N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Imunon, Inc. stock logo
IMNN
Imunon
-$0.24N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
N/A-$1.11N/A-$1.11N/AN/A
5/14/2025Q1 2025
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
-$0.37-$0.13+$0.24-$0.13N/AN/A
5/13/2025Q1 2025
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
$0.10-$0.18-$0.28-$0.18$42.00 million$2.93 million
5/12/2025Q1 2025
Imunon, Inc. stock logo
IMNN
Imunon
-$5.25-$4.20+$1.05-$0.28N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
N/AN/AN/AN/AN/A
Imunon, Inc. stock logo
IMNN
Imunon
N/AN/AN/AN/AN/A
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
N/AN/AN/AN/AN/A
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
N/AN/AN/AN/AN/A

Latest IMNN, COEP, XLO, and LVTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2025
Imunon, Inc. stock logo
IMNN
Imunon
quarterly$0.158.57%8/7/20258/7/20258/21/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
0.02
0.82
0.82
Imunon, Inc. stock logo
IMNN
Imunon
N/A
0.88
0.88
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
N/A
6.73
6.73
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
N/A
1.96
1.96

Institutional Ownership

CompanyInstitutional Ownership
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
13.88%
Imunon, Inc. stock logo
IMNN
Imunon
4.47%
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
N/A
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
54.29%

Insider Ownership

CompanyInsider Ownership
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
24.25%
Imunon, Inc. stock logo
IMNN
Imunon
5.96%
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
9.50%
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
5.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
23.51 million2.66 millionNot Optionable
Imunon, Inc. stock logo
IMNN
Imunon
301.42 million1.34 millionNot Optionable
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
6026.31 million23.81 millionOptionable
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
7051.78 million49.09 millionNot Optionable

Recent News About These Companies

Xilio Therapeutics (NASDAQ:XLO) Shares Down 2.1% - Time to Sell?
Xilio Therapeutics Announces Proposed Public Offering

New MarketBeat Followers Over Time

Media Sentiment Over Time

Coeptis Therapeutics stock logo

Coeptis Therapeutics NASDAQ:COEP

$10.72 +0.12 (+1.13%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$10.42 -0.30 (-2.80%)
As of 08/1/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Imunon stock logo

Imunon NASDAQ:IMNN

$8.50 +0.21 (+2.53%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$8.39 -0.11 (-1.29%)
As of 08/1/2025 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

LAVA Therapeutics stock logo

LAVA Therapeutics NASDAQ:LVTX

$1.42 -0.10 (-6.58%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.42 0.00 (0.00%)
As of 08/1/2025 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Xilio Therapeutics stock logo

Xilio Therapeutics NASDAQ:XLO

$0.65 +0.00 (+0.18%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.65 +0.00 (+0.31%)
As of 08/1/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.